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Varicella-zoster virus (VZV) latency in human dorsal root ganglia is characterized by the tran-
scription of large regions of its genome and by the expression of large amounts of some polypeptides,
which are also expressed during lytic cycles. The immediate early 63 protein (IE63) is a virion
component expressed very early in cutaneous lesions and the first viral protein detected during
latency. Immune response against IE63 has been evaluated among naturally immune adults with
a history of chickenpox: Specific antibodies were detected in serum, and most subjects who had a
T cell proliferation with unfractionated VZV antigens had T cell recognition of purified IE63. The
cytotoxic T cell (CTL) response to IE63 was equivalent to CTL recognition of IE62, the major
tegument component of VZV, whose immunogenicity has been previously described. T cell recogni-
tion of IE63 and other VZV proteins is one of the likely mechanisms involved in controlling VZV
reactivation from latency.
As a member of the Alphaherpesviridae, varicella-zoster vi- then confirmed in human dorsal root ganglia [10]. This protein
is one of the virion components [11]; it is expressed very earlyrus (VZV) shares many characteristics (e.g., neurotropism or
the ability to become latent after a primary infection and to in culture [9] and in skin lesions, in which it is detectable much
earlier than are late proteins, and sometimes it is expressed inreactivate many years later) with the other members of this
virus subfamily (i.e., herpes simplex type 1 or 2 [HSV-1 or the absence of a lesion [12]. During acute infections, IE63
shows mostly a nuclear localization, while it seems to accumu--2]). However, the mechanisms involved in latency of VZV
and HSV-1 and -2 seem to be completely different: During late in cytoplasm of latently infected neurons [10]. However,
it is still unknown whether the protein has the same characteris-HSV latency, the viral genome is found in neurons only, and
transcription is limited to one region of the genome that pro- tics during productive and latent infections or whether differ-
ences (e.g., phosphorylation) can be observed in either case.duces latency-associated transcripts (i.e., antisense of the ICP-
0 transcripts) [1]. These transcripts do not seem to be translated, More recently, other proteins corresponding to the transcripts
and no viral protein has been detected during HSV latency. previously detected during the dormant phase have been de-
On the contrary, the nature of cells in which VZV remains tected in human material [13].
quiescent is still debated because in patient samples, the ge- These observations indicate that the mechanisms involved
nome has been detected in neurons only [2, 3], in satellite cells in VZV latency are completely different from those acting
surrounding neurons only [4], and in both cell types [5]. The in other alphaherpesvirus-infected cells, and the role of viral
most striking difference between HSV and VZV latency is that proteins alone or in interaction with cellular proteins has to be
several immediate early (IE) and early genes of VZV, such as hypothesized.
genes encoding for IE4, IE62, IE63, and MDBP (major DNA One of the parameters that could be critical to the control
binding protein), are transcribed in latently infected rat dorsal of VZV infection is host immunity, as suggested by Hope-
root ganglia [6] and in human ganglia [7, 8]. Moreover, VZV Simpson in 1965 [14]: VZV primary infection is limited by
latency is characterized by the expression of large amounts of the host immune response, which remains high for many years,
IE63, as demonstrated in the rat experimental model [9] and with a slow decrease in time. According to his hypothesis,
frequent virus reactivations or contact with infected persons
could counterbalance this progressive decrease; however, host
resistance may still reach a critical level that is too low to
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Assays for cellular immunity to VZV. Peripheral blood mono-since the herpes zoster episode is not correlated with hypogam-
nuclear cells (PBMC), which had been separated from 50 mL ofmaglobulinemia.
heparinized blood by ficoll-hypaque gradient, were used for TPrevious studies have shown that protein IE62 (the major
lymphocyte proliferation, cytokine, or cytotoxicity assays.tegument protein) and gC, gE, gG, and gI (the major glycopro-
Specific T lymphocyte proliferation was assayed as previouslyteins) are highly immunogenic and elicit a long-term cellular
described [17]. In brief, PBMC were recovered from 50 mL of
immune response after natural VZV infection or immunization
heparinized blood by ficoll-hypaque gradient. Cells were cultured
with a live attenuated vaccine strain (see [15] for review). in 96-well plates at 3 1 105 cells/well and stimulated in triplicate
The immunogenicity of IE63 has not been evaluated, and its with VZV or control antigens or with GST or GST-IE63 fusion
expression during latency and acute infection suggests that this proteins (3–25 mg/mL) whose concentration had been optimized
protein probably plays a crucial role and could be an important previously. Preliminary experiments done with a broad range of
fusion protein concentration (3–100 mg/mL) indicated that withtarget for the immune system.
25 mg/mL, the response to GST alone was too high. Phytohemag-As previously described [16], we have evaluated the immune
glutinin (100 mg/mL) and RPMI 1640 were used as positive andresponse against IE63 among 15 healthy adults with a history
negative controls, respectively. After 5 days, T cell proliferationof chickenpox as verified by detection of anti-VZV IgG anti-
was measured by [3H]thymidine uptake and expressed as a stimula-bodies. As controls, we used 2 healthy adults who had no
tion index (i.e., the ratio of mean counts per minute [cpm] in VZVhistory of varicella and no measurable anti-VZV antibodies.
or GST-IE63–stimulated wells to that of control or GST wells).
All experiments were done with the IE63 protein, which was
A stimulation index⁄2.0 was conventionally defined as a positive
expressed in bacteria and fused to glutathione-S-transferase response.
(GST), as a stimulating antigen [9]. The IE63-specific cytotoxic response was detected by use of
limiting-dilution assays and compared with the cytotoxic T lym-
phocyte response to IE62 as previously described [16]. EffectorMaterials and Methods
cells were either CD4/ and CD8/ cell populations or unfraction-
Study populations. Blood was obtained from 15 healthy adults ated T cells recovered from PBMC by separation with Lympho-
with a history of varicella as confirmed by detection of IgG anti- kwik-T (One Lamba, Los Angeles). CD4/ and CD8/ cells were
bodies to VZV by ELISA. Two healthy adults who had no history purified by positive selection with magnetic cell sorting (MACS;
of varicella and no measurable VZV IgG antibodies served as Miltenyi Biotec, Auburn, CA) [16], and their purity was verified
controls. by fluorescence-activated cell sorter analysis: Positive selections
GST and GST-IE63 production and purification. The GST and yielded⁄90% CD4/ or CD8/ cells. The contaminating population
GST-IE63 proteins were produced from the plasmids pGex-3X was£5%, and CD16/ cells constituted£10% of the effector cells
and pGex-3X/ORF63, which have been described [9]. In brief, in all experiments.
plasmid-transformed bacteria were induced by 1 mM isopropyl- VZV-specific effector T cells were generated by incubation (2
b-D-thiogalactopyranoside for 3 h at 377C, pelleted, and sonicated weeks in 24-well plates) of 2 1 106 cells/well with whole VZV
in PBS Triton X-100 (1% wt/vol). The GST and GST-IE63 pro- antigen in the presence of 106 autologous irradiated PBMC (2700
teins that were released into the supernatant were purified by affin- rads) as feeders. Cells were refed every third day with 10% fetal
ity chromatography on glutathione-Sepharose-4B (Pharmacia- calf serum, VZV antigens, and 10 U/mL recombinant human in-
LKB, Uppsala, Sweden) and eluted with reduced glutathione (10 terleukin (IL)-2 (R&D Systems, Minneapolis). Target cells were
mM). The proteins were quantified by use of a Bradford assay autologous Epstein-Barr virus–transformed B cells that were in-
(Bio-Rad, Hercules, CA) and loaded onto SDS–10% polyacryl- fected with vaccinia recombinants expressing IE62 or IE63 [15].
amide gel to verify their purity. Mock-infected targets or cells infected with vaccinia virus devoid
Whole VZV antigen preparation. Melanoma cells cultured in of any VZV gene were used as controls. After 14 h of incubation
Dulbecco’s modified Eagle medium supplemented with 10% fetal at 377C, targets were centrifuged, resuspended in culture medium,
calf serum were infected with a laboratory strain (Chase) of VZV, and incubated with 300 mCi of 51Cr (Amersham) for 4 h. Labeled
dispersed with glass beads when 90% cytopathic effect was ob- cells were washed, resuspended at 3 1 104 cells/mL, and added
served, washed with PBS, and sonicated for 60 s. After centrifuga- to 96-well V-bottom plates at 3 1 103 cells/well in 0.1 mL.
tion at 47C for 10 min, supernatants were frozen and thawed three To measure cytotoxicity, effector cells were added to lymphoid
times, and aliquots were stored at 0707C. An uninfected cell con- cell line targets at effector-to-target ratios of 30:1, 15:1, 3:1, 1:1,
trol was prepared in parallel. and 1:3 in 8-well replicates. After 4 h at 377C, 51Cr release was
Western blot assay. Western blot analysis was used to deter- measured by counting 100 mL of supernatant in a gamma counter.
mine if anti-IE63 antibodies were in the sera. Purified GST and The spontaneous release of 51Cr and the maximum release after
GST-IE63 were electrophoresed and transferred onto a nylon mem- lysis with 1% Nonidet P40 detergent were determined for each
brane. To avoid nonspecific labeling, the membrane was saturated target cell preparation. The percentage of specific lysis was calcu-
with nonfat milk (5 g/L). The membrane was incubated for 1 h at lated for each target as the [(mean experimental release) 0 (mean
room temperature with the donor’s serum (1/250), washed, and spontaneous release)]/[(mean maximal release)0 (mean spontane-
incubated with a peroxidase-conjugated anti-human IgG (1/2000, ous release)] 1 100.
Dakopatts, Glostrup, Denmark). Antibodies were detected using a Lysis of VZV-specific targets was considered specific when it
Western blotting detection reagent (ECL; Amersham Life Science, was at least 10% higher than lysis of control targets. The responder
cell frequency (RCF) for each assay was determined by applyingAmersham, UK).
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the maximum likelihood method to standard limiting-dilution
plots, using a computerized analysis [18]. Replicates were scored
as positive if the cpm was higher than the mean cpm for the
corresponding spontaneous release plus 3 SD.
Assays for cytokine production. Cytokine production was eval-
uated by stimulating 3 1 105 PBMC with GST-IE63 antigen or
GST (1.25 mg/well) in 96-well plates. Supernatants were harvested
from replicate wells on days 2, 4, and 6 and tested for IL-2, g-
interferon (g-IFN), and IL-4. Cytokine release was quantitated by
use of commercial ELISAs with sensitivities of detection defined
by reference standards in each assay. The cytokine response was
calculated as the amount of cytokine produced with GST-IE63
minus the amount elicited by GST. Commercial assays were used
to measure IL-2 (Genzyme, Cambridge, MA) and g-IFN (Endo-
gen, Cambridge, MA). The presence of IL-4 was assessed using
an ultrasensitive assay (Cytoscreen; BioSource International, Ca-
marillo, CA).
Results
The presence of anti-IE63–specific antibodies was deter-
mined by use of Western blot analysis with GST-IE63: Serum
from all VZV-immune subjects bound to a band corresponding
to IE63, indicating the presence of specific antibodies. This
anti-IE63 humoral immune response was not quantified, but
the faint reactivity in Western blotting indicated that concentra-
tions of IE63-specific antibodies were low in naturally immune
Figure 1. Proliferation induced by stimulation of T cells with un-subjects. No reactivity to IE63 was observed with control sera.
fractionated VZV antigens or with immediate early (IE) 63 protein.
Since cell-mediated immunity seems to be the most im- Stimulation index (SI) for each subject was calculated as ratio between
portant criteria in latency, as previously discussed, we searched mean counts per minute for GST-EI63–purified protein or VZV anti-
for a memory immune response to IE63 by T cell lymphoproli- gens and GST-purified protein or control antigen. Mean SI { SE is
indicated by black square with error bars.feration and cytotoxicity assays.
After samples were stimulated with VZV antigens, the stimu-
lation index (SI) in those from the VZV-immune subjects
ranged from 2.1 to 52 (mean, 14.3 { 10.2 [SE]) (figure 1), in all samples from VZV-immune subjects. This g-IFN produc-
tion was lower in the PBMC cultures of the 2 VZV-immunewhile the SIs in samples from the nonimmune subjects were
2.1 and 1.6. The SI after stimulation with GST-IE63 was 1.2 subjects, who had a low SI in response to IE63 stimulation.
These results have to be compared with the absence of g-IFNand 1.4 for the nonimmune subjects and ranged from 1.8 to
8.0 (mean, 3.4 { 1.5) for the VZV-immune subjects. Among in the samples from nonimmune subjects and are in accordance
with the pattern observed in T cells stimulated in standardthe 15 immune subjects, 9 (60%) had a clear T cell proliferation
in response to GST-IE63; the remaining 6 (40%) had an SI of PBMC culture with unfractionated VZV antigens [19].
However, the absence of measurable IL-2 and IL-4 could2.0 despite SIs to VZV antigen ranging from 5.4 to 11.0. How-
ever, the latter showed a strong stimulation with GST alone, be explained by the fact that these cytokines could be produced
very early and could be bound directly to their receptors, thusmaking difficult any interpretation of the specific stimulation
by IE63. No correlation was found between the magnitude of being undetectable by the techniques used in this study. In this
case, it would be useful to search for the cytokines earlierthe SI measured in response to GST-IE63 and total VZV anti-
gens (data not shown). after stimulation or to search for their transcripts by reverse
transcript–polymerase chain reaction. It is also likely that theFor 6 immune and 2 nonimmune subjects, we measured the
cytokine release by PBMC stimulated with IE63 for 2, 4, or 6 production of some cytokines is regulated by other ones. Even
if the detection of other cytokines is needed to confirm thesedays. IL-2, IL-4, and g-IFN released in the culture supernatant
were quantified by ELISA. The results were expressed as the preliminary observations, g-IFN production indicates that T
cell stimulation by IE63 leads mostly to a Th1 proliferation anddifference between the cytokine concentration detected after
stimulation by GST-IE63 and by GST alone (table 1). IL-2 that the cytolytic component of cellular immunity is enhanced.
Using unfractionated T cells from 4 patients, we observedand IL-4 were not detected; however, significant amounts (50–
1400 pg/mL), with a peak on day 4, of g-IFN were measured the lysis of targets expressing IE63 (27%–43%). This lysis
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Table 1. Interferon-g (IFN-g) production by IE63-stimulated pe- the immune response to other major VZV immunogenic pro-
ripheral blood mononuclear cells from 6 VZV-immune and 2 nonim- teins, such as IE62 and gE.
mune subjects with no history of varicella infection. The implication of IE63 recognition by the immune system
in the control of latency has to be documented using animalSubject no. SI IFN-g* (pg/mL)
models or by studies involving more subjects, especially sub-
Immune subjects jects with a high probability to reactivate the virus. In fact, one
1 2.9 750 of the main characteristics of IE63 is the fact that it is expressed
2 2.2 1400 during productive infection and during latency. This raises the
3 7.4 500
question of the relationship between the immune system and4 8.0 625
the nervous system. Indeed, the nervous system is protected5 2.0 175
6 2.0 50 from immune recognition by physical barriers first and then
Nonimmune subjects by the absence of classical MHC molecules at the surfaces of
7 1.2 50 neurons. On the contrary, satellite cells surrounding neurons
8 1.2 50
express MHC and could play an important role in antigen
NOTE. IFN-g was measured on days 2, 4, and 6 of stimulation, and levels presentation. It is therefore critical to clearly define in which
correspond to maximum amount detected. SI  stimulation index. cells the virus remains quiescent: Viral genomes have been
* Expressed as difference between IFN-g concentration detected after stimu-
detected in neurons only, in satellite cells only, and in bothlation by glutathione-S-transferase (GST)-IE63 and by GST alone.
cell types, whereas IE63 protein has been observed only in
neuron cytoplasm during latency. If neurons are the only cells
expressing viral antigens, the mechanisms leading to the recog-
was equivalent to that observed with targets expressing IE62
nition of viral peptides has to be clarified. It is possible that
(25%–48%) and was significantly higher than that observed
nonclassical MHC proteins are expressed at the cell surface in
for mock-infected or vaccinia-infected targets used as controls.
response to viral infection as has been suggested for HSV
The mean effector frequency for T cells that recognized IE63
infection [20]. However, in HSV-infected cells, peptide presen-
was 1:31,000 { 16,000 SE and was not significantly different
tation by MHC molecules seems to be impaired because of a
(P  .8) than the RCF for cells expressing IE62 (1:44,500 {
viral protein that inhibits peptide processing [21–22]. Such a
22,500 SE).
mechanism has not been demonstrated for VZV and must be
Both CD4/ and CD8/ T lymphocyte populations lysed IE63
explored.
and IE62 targets, as demonstrated by assays using purified
It will be of interest to characterize the immune response to
CD4/ and CD8/ populations as effectors. The RCF of CD8/
IE63 in elderly and immunocompromised subjects, who have
cells recognizing IE63 (1:30,500{ 13,700 SE) was not statisti-
a high incidence of herpes zoster, to examine possible correla-
cally different (P .9) from the RCF of CD8/ cells recognizing
tions between the risk of virus reactivation and diminished
IE62 (1:28,500{ 10,100 SE), indicating that both viral proteins
responses to IE63. Enhancing the immune response to IE63
were recognized with the same efficiency by CD8/ cells. In
protein may be an important strategy to prevent VZV reactiva-
the case of IE63 recognition, the frequency of T cells lysing
tion from latency. If it is, IE63 protein could be a suitable
IE63 targets was equivalent (P  .97) for CD4/ (1:31,450 {
candidate for incorporation into a therapeutic VZV vaccine for
7500 SE) and CD8/ populations of effector cells.
administration to a population at high risk for herpes zoster.
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